Carlyle, Stirling Square Capital Partners, Novo Nordisk, and Miura Partners bid to acquire HealthTech BioActives from Riverside for approximately EUR 300m
Carlyle, Stirling Square Capital Partners, Novo Nordisk y Miura Partners pujan por adquirir HealthTech BioActives a Riverside por aproximadamente EUR 300m
Intel ID : 400632
|
||||
Ultimate Owner (Buyer)
|
Target
|
Bidder
|
|||||||||||||
Seller
|
| Intel ID | 400632 | ||||
| Value | EUR 300,00m (Approx.) | ||||
| Native Currency | Euro (EUR) | ||||
|
Financial Data - HealthTech BioActives
(31 Dec 2021) |
Revenue: EUR 65,32m EBITDA: EUR 18,33m Net Debt: EUR 72,87m People: 141 |
||||
| Date |
 |
||||
| Country | |
||||
| Geography |  |
||||
| Subsector (Old TTR Sectors) |
|
||||
| Primary Subsector (TTRSC) |
25.01.09 Private Equity (Primary) 25 Financial Services / 25.01 Banking & Investment 30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 25.01.01 Asset Management (Primary) 25 Financial Services / 25.01 Banking & Investment |
||||
| Secondary Subsectors (TTRSC) |
25.04.03 Holding Companies / Financial Holding Companies 25 Financial Services / 25.04 Other Financial Services 15.05.05 Drug Stores & Pharmacies 15 Consumer Products & Services / 15.05 Distribution & Retail 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||||
| Type |
|
||||
| Intel Grade |
|
||||
| Source |
|
||||
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
15.05.05 Drug Stores & Pharmacies 15 Consumer Products & Services / 15.05 Distribution & Retail |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Seller
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Ultimate Owner (Buyer)
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.01 Asset Management 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Financial Advisory
| Parties | Advisor | Notes from Advisors | |||||
|---|---|---|---|---|---|---|---|
|
|
- |
Legal Advisory
| Parties | Advisor | Type | Notes from Advisors | |||||
|---|---|---|---|---|---|---|---|---|
|
|
- | - |
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.